Drug Development Solutions

What Drug Development Solutions does

Drug Development Solutions, operating under the brand name Resolian, is a global bioanalytical and analytical sciences contract research organization (CRO) headquartered in Fordham, United Kingdom. Founded in 1982, the firm provides GLP- and GCP-compliant testing services to pharmaceutical and biotechnology sponsors across the full drug development lifecycle — from discovery through commercial — under three service pillars: Bioanalytics (small and large molecule LC-MS/MS, flow cytometry, immunoassay, high-resolution mass spectrometry, PCR, immunogenicity, biomarker and DMPK/ADME analysis), Analytical Sciences (formulation development, nitrosamines, extractables and leachables, materials characterization, impurity and elemental analysis), and Supporting Sciences (PK/TK statistical analysis, regulatory submission support, global quality assurance). Resolian operates five laboratories across four countries — Malvern (USA), Fordham and Sandwich (UK), Brisbane (Australia), and Chongqing (China) — with harmonized SOPs and a single project management interface designed to allow assay transfer and multi-region study execution.

The company is privately held, employs between 251 and 500 people, and serves over 200 pharmaceutical and biotech customers, including both large pharma sponsors and biotechs from startup to large-cap. Revenue is generated through project-based, quote-priced professional services contracts rather than subscription or per-unit pricing, with project scope and complexity driving economics. The firm positions itself on regulatory credibility (30+ years of combined FDA, EMA, and MHRA inspection readiness), global harmonization, PhD-level scientific engagement, and domain specialization in advanced modalities including cell and gene therapy, antibody-drug conjugates, and oligonucleotides/proteins.

Senior leadership includes CEO Patrick Bennett (35+ years across Thermo Fisher, LabCorp, and PPD) and CSO Dr. Zhiyang Zhao (30+ years across Pfizer, GlaxoSmithKline, and Amgen, including a decade as Site Director of Preclinical Research at Amgen). The business operates as an independent, privately held entity with no disclosed parent company, institutional investor, funding rounds, or M&A activity in the source data.

Name

Drug Development Solutions

Legal name

Resolian Inc.

Website

https://www.drugdevelopmentsolutions.com/

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

251–500 employees

Short description

Resolian (Drug Development Solutions) is a global bioanalytical and analytical sciences CRO operating five labs in four countries, providing GLP/GCP testing services in LC-MS/MS, immunoassay, flow cytometry, and biomarker analysis to over 200 pharmaceutical and biotech sponsors.

Ownership category

akta.pro rank

Product category

Contract Bioanalytical Research and Analytical Sciences Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Small-Molecule Analytical Development & Method Validation (CMC) (HLAGAHAF), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Bioanalytical CRO services
• Pharmaceutical analytical testing
• Drug development bioanalysis
• LC-MS/MS bioanalysis
• Biomarker analytical sciences

Headquarters

HQ city

Fordham

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Bioanalytical Testing Services: Contract research organization providing bioanalytical testing for pharmaceutical and biotech companies across all phases of drug development. Revenue is generated through project-based contracts for method development, validation, and sample analysis services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Drug Development Solutions (operating as Resolian) is a global bioanalytical and analytical sciences contract research organization providing GLP and GCP-compliant testing services across all phases of drug development. The company delivers method development and validation, sample analysis, biomarker quantification, immunogenicity testing, PK/ADA/NAb assays, formulation development, nitrosamines testing, materials characterization, extractables and leachables studies, and regulatory submission support through five laboratories across four continents.

Product overview

Resolian operates as a unified global bioanalytical and analytical sciences CRO offering three interconnected service pillars: Bioanalytics (large/small molecule LC-MS/MS, flow cytometry, immunoassay, PCR, and biomarker analysis), Analytical Sciences (formulation development, nitrosamines testing, materials characterization, extractables/leachables), and Supporting Sciences (PK/TK analysis, regulatory submission support, global quality assurance). The company maintains five laboratories across four continents (USA, UK, Australia, China) delivering consistent quality under harmonized SOPs, serving over 200 pharmaceutical and biotech clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioanalytics Advanced bioanalytical testing for drug development including large and small molecule bioanalysis (PK, ADA, NAb), biomarker analysis and pharmacodynamics, ADME/DMPK services, and method development and validation, serving pharmaceutical and biotech sponsors across all phases of drug development.
• Analytical Sciences Quality testing and characterization services including method development and validation for diverse applications, stability studies and product characterization, materials science and elemental analysis, formulation development, nitrosamines testing, extractables and leachables, and impurity identification for pharmaceutical sponsors.
• Supporting Sciences Specialized expertise for complex analytical challenges including regulatory submission support and eCTD publishing, PK/TK parameter assessment, global quality assurance, document production, and custom testing solutions and method transfers for pharmaceutical development programs.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Charles River Laboratories: Global, large-cap CRO with a dedicated bioanalytical / safety assessment business that serves the same pharma and biotech sponsors; competes with Resolian on preclinical and bioanalytical scopes but as part of a much broader service portfolio.
• Eurofins Scientific: Global testing services group with significant bioanalytical, pharmaceutical, and central laboratory capabilities across multiple continents, directly competing with Resolian on bioanalytical and analytical sciences work.
• WuXi AppTec: One of the largest global CROs/CDMOs with extensive bioanalytical and DMPK capabilities in China and the US, directly competing with Resolian for both small and large molecule bioanalytical studies, particularly given shared Chinese laboratory presence.
• Labcorp (Covance): Global clinical and bioanalytical laboratory services provider; Resolian's CEO previously led strategy at Labcorp, and the company directly competes on bioanalytical, central lab, and early-phase services.
• PPD (Thermo Fisher Scientific): Global CRO offering bioanalytical and clinical research services across all phases; Resolian's CEO previously served as VP at PPD, and the firm competes on large-scale bioanalytical scopes tied to global clinical programs.

Direct peers

• Frontage Laboratories: US-headquartered contract research organization providing bioanalytical, CMC, and DMPK services to pharma and biotech; very similar business mix and customer base to Resolian, especially in small and large molecule LC-MS/MS bioanalysis.
• KCAS Bioanalytical: Specialty bioanalytical CRO focused on small and large molecule PK, immunogenicity, and biomarker analysis using LC-MS/MS and immunoassay; competes head-to-head with Resolian for biotech and pharma bioanalytical work.
• SGS Life Sciences: Global life sciences testing services group providing bioanalytical, analytical, and clinical research services across multiple geographies, with a comparable focus on pharma and biotech sponsors.
• Pharmaron: China-rooted global CRO/CDMO with significant bioanalytical, DMPK, and biologics capabilities in the US, UK, and China; competes directly with Resolian, particularly in cell/gene therapy and biologics bioanalysis.
• Intertek Pharmaceutical Services: Global quality assurance and laboratory services provider with pharmaceutical bioanalytical and analytical chemistry capabilities, serving similar pharma/biotech customers in regulated testing scopes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/resolian
• Instagraminstagram.com/weareresolian
• Xx.com/DDSDrugDev

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drug Development Solutions